Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Analyst
Andy Wittmann
Period: Reporting periods mapped to calendar 2024 Q3 – 2026 Q3 (9 quarters).
- Questions
- 28on tracked calls
- Challenge rate
- 14%4 of 28 questions
- Companies
- 3questioned at least once
- Reporting periods
- 9with questions
These figures cover the whole profile: every tracked question, all reporting periods.
How to read these numbers
Challenge rate is the share of questions that pushed back, pressed for specifics or questioned management’s assumptions. It describes how questions were asked on the calls tracked here; it does not measure whether any view turned out to be right.
Rounding. Rates are rounded to whole percentages, so a small share can show as 0% even when some questions were challenging. The count beside each rate is exact; “none of N questions” means no question was challenging.
No questions recorded. “—” means there is nothing to calculate: no questions were recorded for that period on the calls tracked here. It does not mean there was no activity.
Fewer than 3 questions. A company-level rate is withheld when fewer than 3 questions were recorded for that company; the questions are still counted everywhere else.
Small samples. Profiles with fewer than 10 questions are marked Limited sample.
Reporting periods. Questions are grouped by the calendar quarter each company’s fiscal reporting period maps to, not by the date of the call. Periods without a calendar mapping are listed separately under their fiscal label.
Questions asked
Grouped by company, most questions first. Open a company to read its questions, newest reporting period first.
Showing 28 of 28 questions from 3 companies
JJacobs Solutions15 questions · 8 reporting periods · 4 of 15 challenging
Calendar 2026 Q2
what should the investment community expect in terms of income statement adjustments between GAAP and non-GAAP
Show response
Venk said the Q3 GAAP/non-GAAP EPS gap was mainly a tax item and, with M&A off the table, the two measures should converge substantially from Q4.
Calendar 2026 Q1
because you mentioned that there was going to be a fiscal third quarter cash outflow in addition to the substantial cash outflow
Show response
Nathamuni detailed PA transaction charges: $235M compensation expense acceleration in Q2 (P&L and cash), $105M employee benefit trust payments in Q3 (cash only, already in P&L). Restructuring costs declining substantially in FY2026 versus FY2025.
if those out-year drivers are any different from the ones that you've been realizing here over these last 2 very strong years
Show response
Nathamuni confirmed margin initiatives well underway with global delivery increasing in pace, scope, and scale. AI deployment in enterprise functions providing leverage without raising CapEx (maintained at 1% of revenue) through reallocation from traditional SaaS to AI investments.
Calendar 2025 Q4
the math that I get here from the multiple is substantially larger than the 13 times
Show response
Nathamuni and Subin explained the gap between accounting and economic ownership due to employee benefit trust c-shares, clarifying 40% stake acquired at 13x EBITDA (12.3x including synergies), with NCI reduced by after-tax amount creating apparent multiple discrepancy.
I'd wanna ask about how you're managing the risk criteria here
Show response
Pragada confirmed risk profile unchanged from 20-year EPCM delivery model used in life sciences and water, with same flow-through approach to supply chain on current awards.
Calendar 2025 Q3
it is under the 100% targets. And I was wondering what the items in the '26 outlook are that bridge you
Show response
Nathamuni explained FY2026 FCF guidance includes a one-time tax event unrelated to continuing operations and expected cash expenses from PA acquisition resolution, while underlying cash flow efficiency continues improving.
what was it about the environmental side that caused a little bit of softness? Would you tie that to anything?
Show response
Pragada identified three drivers: regulatory volatility causing private sector client pullbacks among large industrials and chemical companies, FEMA disaster relief funding transfer from federal to state level creating award delays, and a one-time prior-year comp from a federal agency outside the US.
Calendar 2025 Q2
the puts and takes associated with the One Big Beautiful bill here. Obviously, there's a lot of new policy
Show response
Pragada identified positives: DoD infrastructure, FAA opportunities, reshoring backstop. Potential take: Medicaid cuts impacting state/local budgets, but clients not raising this yet.
update us on where you are seeing the onetime costs associated with the split?
Show response
Nathamuni confirmed on track for $75-95M restructuring in FY2025 (down ~3x from prior year), expecting further dramatic decline in FY2026.
Calendar 2025 Q1
help us understand how you get to the 100% greater than 100% conversion this year in terms of the quarterly cadence?
Show response
Nathamuni confirmed substantial Q3 cash flow step-up, not solely Q4-loaded, driven by seasonal patterns and lower cash tax payments.
discuss where your utilizations rate -- your utilization rates stand this year as compared to last year
Show response
Pragada noted utilization dipped in January from holiday spillover but has recovered and is exceeding prior quarters in early Q3 as large project backlogs enter production phases.
Calendar 2024 Q4
is the focus on TTM, a reflection of like the next couple of quarters of awards that, maybe are a little bit softer
Show response
Pragada explained TTM smooths lumpy large project wins; 19% backlog growth and double-digit growth for several consecutive quarters demonstrate underlying strength.
Is that right, right now, are you losing on a GAAP basis, $4 million on the TSA?
Show response
Nathamuni confirmed TSA is profitable and its expiration represents a margin opportunity, not a headwind.
Calendar 2024 Q3
as you look at '26, do you feel like '26 is the year that we get pretty clean results?
Show response
Pragada confirmed FY2026 will have clean results, with restructuring costs decaying significantly in the second half of FY2025.
your backlog is up 22.5% year-over-year, which is great. But your revenue guidance is up, mid to high-single digits. That seems like a really wide gap
Show response
Pragada explained the gap is due to multiyear project duration, not margin dilution, and confirmed large bookings are at or above corporate margins.
CTASCintas8 questions · 4 reporting periods · 0 of 8 challenging
Calendar 2026 Q3
You're guiding your net interest expense increasing for the year
Show response
Scott explained bridge-loan financing fees (~$6 million over 18 months, about $4 million in FY2027) hit net interest expense; the $103 million guide is unchanged for Q2 to Q4.
I just wanted to ask my follow-up on the FIRE segment and the implementation of the SAP system.
Show response
Jim said SAP is still in pilot in Fire Protection, not yet live, with rollout expected during the fiscal year; it is not affecting guidance or results.
Calendar 2025 Q4
Maybe, Todd, you could just talk about kind of the funnel here. Do you feel like thinking about the amount of capital deployment last year is again doable this year with the progress that you made ...
Show response
Strong Q2 capital allocation: $100M+ CapEx, $85M M&A across all 3 route-based businesses, $182M dividends, $600M+ buybacks. M&A unpredictable but pipeline actively managed with decades-old relationships.
over the last couple of years, you've had some competitors that have really gone on volume chasing spree. You guys have obviously executed very well amongst all this, but I was just wondering what ...
Show response
Competitive environment unchanged. Focus on no-programmer conversion, not competitor wins. Retention at all-time highs. Over 2/3 of new customers from no-programmer market.
Calendar 2025 Q3
do you think that fiscal '26 is a higher investment year in some of these things like route leadership, management trainees, technology than it was in 2025
Show response
More timing than step-up in investment level. Heavier investment began in Q4 FY2025, continuing into FY2026. Outlook for First Aid business remains very positive.
On the First Aid segment gross margins, they were down a decent amount year-over-year. And I was wondering if you could help us understand what either happened this quarter that caused them to be d...
Show response
First Aid gross margin flat sequentially despite tough YoY comp. Investments in route capacity, leadership bench, technology, and selling resources. Timing issue, not structural.
Calendar 2024 Q4
it kind of feels like there's been more national account business that's kind of hit the market and its traded hands
Show response
CEO deflected from national accounts, pivoting to growth via no-programmer new business. Said focus is expanding the pie rather than competing for share.
could you just talk about any categories in particular? Obviously, you called out the energy, always call it the energy, but maybe other key categories
Show response
CFO provided detailed breakdown: garment sharing reducing amortization, automated sortation improving production, SmartTruck reducing routes and idling.
ECLEcolab5 questions · 5 reporting periods · 0 of 5 challenging
Calendar 2026 Q1
the total customers that you expect to approach with the energy surcharge versus how many you've approached today
Show response
Beck confirmed universal surcharge across all customers, businesses, and 172 countries. Started April 1 and progressing well. Objective to be mostly done by end of Q2/early Q3.
Calendar 2025 Q4
Scott, I was wondering if you could talk about the FX rates that are implicit in your EPS guidance raise
Show response
Kirkland guided FX neutral for 2026 (slightly favorable H1, neutral H2). Tax rate up to 20.5-21.5% from 20.2%. Other income headwind of ~$20M from pension assumptions. Beck confirmed net new business at record levels even in challenged businesses like Basic Industries and Paper.
Calendar 2025 Q3
Just wondering if you could just help us understand a little bit about how that top line is affecting that segment's margin performance?
Show response
Beck quantified Water ex Basic Industries and Paper at 4% top line and 15% OI growth. New Pest customer is entirely new (not conversion), attracted by technology after seeing major retailer success. 400K devices deployed, targeting 1M by H1 2026.
Calendar 2025 Q2
do you still expect it to be a 95% year? And maybe what happened in the first half?
Show response
Kirkland guided to ~90% FCF conversion for full year, slightly below 95% target due to elevated CapEx at 7%. Q2 FCF up 17% YoY. Q1 had unfavorable YoY comp from cash payment timing.
Calendar 2025 Q1
what do you think the approximate revenue level needs to be in life sciences to deliver something on that order of magnitude?
Show response
Beck declined to specify revenue target but described long-term investments in UK biotech plant, US E1 facility, Asia capacity, SAP platform, and R&D.
Challenge rate by company
Every company this analyst questioned, most questions first. A company-level rate is shown from 3 questions; below that it is withheld.
| Company | Questions | Challenge rate |
|---|---|---|
| J Jacobs Solutions | 15 | 27%4 of 15 questions |
| CTAS Cintas | 8 | 0%none of 8 questions |
| ECL Ecolab | 5 | 0%none of 5 questions |
Activity by reporting period
Questions recorded for each calendar quarter that companies’ reporting periods map to (not the call date), with the challenge rate for that period. Periods inside the range with no questions are shown as “No questions recorded”.
| Calendar period | Questions | Challenge rate | Companies |
|---|---|---|---|
| 2024 Q3 | 2 | 50%1 of 2 questions | 1 |
| 2024 Q4 | 4 | 25%1 of 4 questions | 2 |
| 2025 Q1 | 3 | 0%none of 3 questions | 2 |
| 2025 Q2 | 3 | 0%none of 3 questions | 2 |
| 2025 Q3 | 5 | 20%1 of 5 questions | 3 |
| 2025 Q4 | 5 | 20%1 of 5 questions | 3 |
| 2026 Q1 | 3 | 0%none of 3 questions | 2 |
| 2026 Q2 | 1 | 0%none of 1 question | 1 |
| 2026 Q3 | 2 | 0%none of 2 questions | 1 |
- 2024 Q32 questions · challenge rate 50% (1 of 2 questions) · 1 company
- 2024 Q44 questions · challenge rate 25% (1 of 4 questions) · 2 companies
- 2025 Q13 questions · challenge rate 0% (none of 3 questions) · 2 companies
- 2025 Q23 questions · challenge rate 0% (none of 3 questions) · 2 companies
- 2025 Q35 questions · challenge rate 20% (1 of 5 questions) · 3 companies
- 2025 Q45 questions · challenge rate 20% (1 of 5 questions) · 3 companies
- 2026 Q13 questions · challenge rate 0% (none of 3 questions) · 2 companies
- 2026 Q21 question · challenge rate 0% (none of 1 question) · 1 company
- 2026 Q32 questions · challenge rate 0% (none of 2 questions) · 1 company
Topics
Topics tagged on this analyst’s questions.
- Margin13
- M&A7
- Capital Allocation6
- Cost Pressure5
- Demand5
- Competitive Dynamics4
- Revenue Growth3
- Innovation & R&D2
- Pricing2
- Regulation Policy2
Show all 13 topics
- Guidance Reliability1
- Capex Investment1
- Fx1